Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | FABP4 | P15090 | 2/20 | 0.49 |
| ▸ | BRD2 | P25440 | 1/20 | 0.49 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16660682 | 0.77 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19PKM | |
| SCHEMBL5960104 | 0.77 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MAPT | |
| SCHEMBL31113449 | 0.76 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19PKM | |
| SCHEMBL19931427 | 0.76 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19PKM | |
| SCHEMBL16715360 | 0.76 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19PKM | |
| SCHEMBL16658373 | 0.75 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19PKM | |
| SCHEMBL31658287 | 0.74 | CYP1A2 (0.70) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19PKM | |
| SCHEMBL1905580 | 0.74 | SMN1; SMN2 (0.55) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19PKM | |
| SCHEMBL1905577 | 0.74 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19PKM | |
| SCHEMBL28699989 | 0.74 | HTR6 (0.65) | ALDH1A1PKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105828820-A | Bromodomain inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2016-08-03 | — | — | CN | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | ALDH1A1 4287/4885SMN1; SMN2 1178/4885CYP1A2 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.